Phase 2 Study of Oral K201 for Prevention of AF Recurrence

Summary

To evaluate the safety, efficacy, and tolerability of 3 doses of K201 (oral) administered for up to 28 days in subjects with recent DC cardioversion to sinus rhythm from sustained symptomatic atrial fibrillation (AF duration \>3 days and \<6 months).

Timeline

Start

2010-04

Primary completion

2011-10

Completion

2011-12

Drugs

Indications